Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum

Cullinan Therapeutics (CGEM) will participate in a fireside chat at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 24, 2026, at 1:30 p.m. ET.

Rhea-AI Summary

Cullinan Therapeutics (CGEM) will participate in a fireside chat at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 24, 2026, at 1:30 p.m. ET.

Chief Executive Officer Nadim Ahmed and Chief Medical Officer Jeffrey Jones will represent the company. A live webcast of the session will be accessible via the Events and Presentations section of Cullinan’s investor relations website. Cullinan is a clinical-stage biopharmaceutical company focused on developing potential first- or best-in-class, disease-modifying T cell engagers for autoimmune diseases and cancer, leveraging its expertise in T cell engagers that are established in oncology and extending them into autoimmune indications.

Key Terms

t cell engagers

1 terms

t cell engagers technical

"developing potential first- or best-in-class, disease-modifying T cell engagers"

T cell engagers are engineered molecules that act like a matchmaker or bridge, linking a patient’s T cells (immune cells that kill infected or cancerous cells) directly to diseased cells so the immune system can destroy them. For investors, they matter because successful T cell engagers can become high-value therapies with steep clinical and regulatory milestones that drive a biotech company’s revenue potential and share price, while failures or safety issues can rapidly reduce valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 1:30 p.m. ET.

A webcast of the fireside chat will be available under the Events and Presentations section of the Company’s investor relations website at https://investors.cullinantherapeutics.com/events.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company developing potential first- or best-in-class, disease-modifying T cell engagers for autoimmune diseases and cancer. Cullinan pursues promising therapeutic targets while leveraging core expertise in T cell engagers, which are established in oncology and are now advancing into autoimmune diseases. With a clinical-stage pipeline built on a rigorous scientific approach and purposeful innovation, Cullinan is advancing its mission to deliver new standards of care for patients. Learn more about Cullinan at https://cullinantherapeutics.com/, and follow Cullinan on LinkedIn and X.

Contacts:

Investors
Nick Smith
+1 401.241.3516
Nsmith@cullinantx.com

Media
Rose Weldon
+1 215.801.7644
Rweldon@cullinantx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How can investors access the Cullinan Therapeutics fireside chat at the Stifel 2026 Virtual Immunology and Inflammation Forum?

The webcast of Cullinan Therapeutics’ fireside chat will be available through the Events and Presentations section of the company’s investor relations website at https://investors.cullinantherapeutics.com/events.